Consenso mexicano sobre el síndrome de intestino irritable

Chey, 2015, Irritable bowel syndrome: A clinical review, JAMA, 313, 949, 10.1001/jama.2015.0954 López-Colombo, 2009, Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable. Epidemiología y fisiopatología, Rev Gastroenterol Mex, 74, 56 Remes-Troche, 2009, Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable. Cuadro clínico y criterios diagnósticos, Rev Gastroenterol Mex, 74, 58 Schmulson, 2009, Guías clínicas de diagnóstico y tratamiento en gastroenterología del síndrome de intestino irritable. Tratamiento, Rev Gastroenterol Mex, 74, 63 Remes-Troche, 2010, Tratamiento farmacológico del síndrome de intestino irritable: Revisión técnica, Rev Gastroenterol Mex, 75, 42 Fink, 1984, Consensus methods: Characteristics and guidelines for use, Am J Public Health, 74, 979, 10.2105/AJPH.74.9.979 Guyatt, 2008, GRADE: An emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Oñate-Ocaña, 2009, Sistema GRADE para clasificar nivel de evidencia y grado de las recomendaciones para la elaboración de guías de buena práctica clínica, Cir Ciruj, 77, 417 Sanabria, 2015, Sistema GRADE: Metodología para la realización de recomendaciones para la práctica clínica, Aten Primaria, 47, 48, 10.1016/j.aprim.2013.12.013 Longstreth, 2006, Functional bowel disorders, Gastroenterology, 130, 1480, 10.1053/j.gastro.2005.11.061 Salhy, 2014, Is irritable bowel syndrome organic disorder?, World J Gastroenterol, 20, 384, 10.3748/wjg.v20.i2.384 Schmulson, 2006, Frequency of functional bowel disorders among healthy volunteers in Mexico City, Dig Dis, 24, 342, 10.1159/000092887 López-Colombo, 2012, The epidemiology of functional gastrointestinal disorders in Mexico: A population-based study, Gastroenterol Res Pract, 2012, 60617, 10.1155/2012/606174 Valerio-Ureña, 2010, Prevalencia del síndrome de intestino irritable en población abierta de la ciudad de Veracruz, Rev Gastroenterol Méx, 75, 36 Amieva-Balmori, 2014, Síndrome de intestino irritable en México. Estudio nacional utilizando cuestionario modular Roma III, Rev Gastroenterol Mex, 79, 22 Schmulson, 2012, The Rome III Adult Questionnaire in Spanish-Mexico has a low sensitivity for identifying IBS and higher sensitivity for uninvestigated dyspepsia, Gastroenterology, 142 Engsbro, 2013, Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care, Am J Gastroenterol., 108, 972, 10.1038/ajg.2013.15 Schmulson, 2007, Further validation of the IBS-QOL: Mexican female IBS patients have poorer quality of life than females from North Carolina, Dig Dis Sci, 52, 2950, 10.1007/s10620-006-9689-9 Reséndiz-Figueroa, 2008, Impacto de los rasgos de ansiedad y depresión sobre aspectos clínicos y calidad de vida en pacientes con síndrome de intestino irritable, Rev Gastroenterol Mex, 73, 3 Remes-Troche, 2008, El papel del abuso físico, psicológico y sexual en los trastornos funcionales digestivos. Un estudio de casos y controles, Rev Gastroenterol Mex, 73, 209 Schmulson, 2000, Los pacientes con trastornos funcionales digestivos (TFD) tienen mayor compromiso de la calidad de vida (CV) evaluada por el SF-36 comparados con pacientes con hepatitis C y pancreatitis crónica, Rev Gastroenterol Mex, 65, 50 Huerta, 2001, Diferencias en la calidad de vida (CV) entre pacientes con síndrome de intestino irritable (SII) y la población mexicana, evaluadas mediante el SF-36, Rev Gastroenterol Mex, 66, 145 Minocha, 2006, Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: A population-based study, Dig Dis Sci, 51, 446, 10.1007/s10620-006-3153-8 Ghoshal, 2012, The gut microbiota and irritable bowel syndrome: Friend or foe?, Int J Inflam., 2012, 151085, 10.1155/2012/151085 Tanaka, 2011, Biopsychosocial model of irritable bowel syndrome, J Neurogastroenterol Motil, 17, 131, 10.5056/jnm.2011.17.2.131 Schmulson, 2012, Abnormal immune regulation and low-grade inflammation in IBS: Does one size fit all?, Am J Gastroenterol, 107, 273, 10.1038/ajg.2011.427 Schmulson, 2014, Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: An evidence-based review, Rev Gastroenterol Mex, 79, 96 Reyes-Huerta, 2010, Intolerancia a la fructosa en pacientes con síndrome de intestino irritable; un estudio de casos y controles, Rev Gastroenterol Mex, 75, 405 Yang, 2014, Lactose intolerance in irritable bowel syndrome patients with diarrhoea: The roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity, Aliment Pharmacol Ther, 39, 302, 10.1111/apt.12582 Zhu, 2013, Bloating and distention in irritable bowel syndrome: The role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency, Am J Gastroenterol, 108, 1516, 10.1038/ajg.2013.198 Pérez, 2015, Respuesta clínica en pacientes mexicanos con síndrome de intestino irritable tratados con dieta baja en carbohidratos fermentables (FODMAP), Rev Gastroenterol Mex, 80, 180 Schmulson, 2015, ¿Una dieta baja en FODMAP mejora los síntomas en pacientes mexicanos con SII?, Rev Gastroenterol Mex, 80, 177 Magge, 2012, Low-FODMAP diet for treatment of IBS, Gastroenterol Hepatol (N Y), 8, 739 Porter, 2011, The incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population, Am J Gastroenterol, 106, 130, 10.1038/ajg.2010.371 Dai, 2012, The incidence and risk factors of post-infectious irritable bowel syndrome: A meta-analysis, Hepatogastroenterology, 59, 67 Schwille-Kiuntke, 2015, Systematic review with meta-analysis: Post-infectious irritable bowel syndrome after travellers’ diarrhoea, Aliment Pharmacol Ther, 41, 1029, 10.1111/apt.13199 Quigley, 2006, Changing face of irritable bowel syndrome, World J Gastroenterol, 12, 1, 10.3748/wjg.v12.i1.1 Schmulson, 2010, Heartburn and other related symptoms are independent of body mass index in irritable bowel syndrome, Rev Esp Enferm Dig, 102, 229, 10.4321/S1130-01082010000400002 Schmulson, 2010, Prevalencia y caracterización de los subtipos de SII según los criterios de Roma III, en un estudio clínico, multicéntrico. Reporte del grupo mexicano de estudio para el síndrome de intestino irritable, Rev Gastroenterol Mex, 75, 427 Halpin, 2012, Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: Systematic review and meta-analysis, Am J Gastroenterol, 107, 1474, 10.1038/ajg.2012.260 Sainsbury, 2013, Prevalence of irritable bowel syndrome-type symptoms in patients with celiac disease: A meta-analysis, Clin Gastroenterol Hepatol, 11, 359, 10.1016/j.cgh.2012.11.033 Engsbro, 2013, Patients suspected of irritable bowel syndrome--cross-sectional study exploring the sensitivity of Rome III criteria in primary care, Am J Gastroenterol, 108, 972, 10.1038/ajg.2013.15 Dang, 2012, Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III, Neurogastroenterol Motil, 24, 10.1111/j.1365-2982.2012.01943.x Jellema, 2009, Systematic review: Accuracy of symptom-based criteria for diagnosis of of irritable bowel syndrome in primary care, Aliment Pharmacol Ther, 30, 695, 10.1111/j.1365-2036.2009.04087.x Ford, 2013, Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care, Gastroenterology, 145, 1262, 10.1053/j.gastro.2013.08.048 Pimentel, 2013, Report from the multinational irritable bowel syndrome initiative 2012, Gastroenterology, 144, e1, 10.1053/j.gastro.2013.04.049 Carmona-Sánchez, 2004, El valor diagnóstico de la investigación limitada en pacientes con síndrome de intestino irritable, Rev Gastroenterol Méx, 69, 24 Carmona-Sánchez, 2007, La detección y tratamiento del hipotiroidismo subclínico en pacientes con síndrome de intestino irritable ¿modifica el uso de recursos de salud?, Rev Gastroenterol Méx, 72, 222 Hamm, 1999, Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria, Am J Gastroenterol, 94, 1279, 10.1111/j.1572-0241.1999.01077.x Cash, 2002, The utility of diagnostic tests in irritable bowel syndrome patients: A systematic review, Am J Gastroenterol, 97, 10.1111/j.1572-0241.2002.07027.x Spiller, 2010, Intestinal disorders, Rev Gastroenterol Mex., 75, 484 Whitehead, 2006, Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome, Aliment Pharmacol Ther, 24, 137, 10.1111/j.1365-2036.2006.02956.x Ford, 2008, Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis, Gut, 57, 1545, 10.1136/gut.2008.159723 Furman, 2011, The role of diagnostic testing in irritable bowel syndrome, Gastroenterol Clin North Am, 40, 105, 10.1016/j.gtc.2010.12.001 Cash, 2011, The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls, Gastroenterology, 141, 1187, 10.1053/j.gastro.2011.06.084 Remes-Troche, 2006, Celiac disease could be a frequent disease in Mexico: Prevalence of tissue transglutaminase antibody in healthy blood donors, J Clin Gastroenterol, 40, 697, 10.1097/00004836-200609000-00007 Remes-Troche, 2013, Celiac disease in Mexican population: An update, Am J Gastroenterol, 108, 10.1038/ajg.2012.408 Sanchez-Vargas, 2013, Prevalence of antibodies related to celiac disease (CD) in patients with irritable bowel syndrome (IBS) according to Rome III criteria. A case-control study, Gastroenterology, 44 Patel, 2015, Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: Cross-sectional survey, Scand J Gastroenterol, 50, 816, 10.3109/00365521.2015.1007079 2009, An evidence-based position statement on the management of irritable bowel syndrome, Am J Gastroenterol., 104, S1 Abboud, 2013, Symptomatic overlap between microscopic colitis and irritable bowel syndrome: A prospective study, Inflamm Bowel Dis, 19, 10.1097/MIB.0b013e31827febfd Stoicescu, 2012, Microscopic colitis - a missed diagnosis in diarrhea-predominant irritable bowel syndrome, Maedica (Buchar), 7, 3 Carmona-Sánchez, 2011, Prevalencia de colitis microscópica en pacientes con criterios del síndrome de intestino irritable con predominio de diarrea, Rev Gastroenterol Mex, 76, 39 Ayala Ibarra, 2008, Utilidad de la colonoscopia en pacientes con síndrome de intestino irritable (SII), Rev Gastroenterol Mex, 73, 160 Francis, 1996, Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome?, Am J Gastroenterol, 91, 1348 O’Connor, 2012, Role of radiologic imaging in irritable bowel syndrome: Evidence-based review, Radiology, 262, 485, 10.1148/radiol.11110423 Rana, 2014, Breath tests and irritable bowel syndrome, World J Gastroenterol, 20, 7587, 10.3748/wjg.v20.i24.7587 Sharma, 2014, Fructose malabsorption is not uncommon among patients with irritable bowel syndrome in India: A case-control study, Indian J Gastroenterol, 33, 466, 10.1007/s12664-014-0492-9 Jamali, 2012, Evaluation of health related quality of life in irritable bowel syndrome patients, Health Qual Life Outcomes, 10, 12, 10.1186/1477-7525-10-12 Coffin, 2004, Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome, Gastroenterol Clin Biol, 28, 11, 10.1016/S0399-8320(04)94834-8 Soares, 2014, Irritable bowel syndrome: A clinical review, World J Gastroenterol, 20, 10.3748/wjg.v20.i34.12144 Däbritz, 2014, Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome, World J Gastroenterol, 20, 363, 10.3748/wjg.v20.i2.363 Chang, 2014, Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome, Mol Med Rep, 10, 10.3892/mmr.2014.2180 Pimentel, 2015, Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects, PLoS One, 10, e0126438, 10.1371/journal.pone.0126438 Sood, 2015, Systematic review with meta-analysis: The accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers, Aliment Pharmacol Ther, 42, 491, 10.1111/apt.13283 Camilleri, 2015, Review article: Biomarkers and personalised therapy in functional lower gastrointestinal disorders, Aliment Pharmacol Ther, 42, 818, 10.1111/apt.13351 Grundmann, 2010, Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for health-care practitioners, J Gastroenterol Hepatol, 25, 10.1111/j.1440-1746.2009.06120.x Halland, 2013, New treatments for IBS, J Nat Rev Gastroenterol Hepatol, 10, 13, 10.1038/nrgastro.2012.207 Drossman, 2014 DiPalma, 2012, The role of effective clinician-patient communication in the management of irritable bowel syndrome and chronic constipation, J Clin Gastroenterol, 46, 748, 10.1097/MCG.0b013e31825a2ff2 Schmulson, 2006, A single session of reassurance can acutely improve the self-perception of impairment in patients with IBS, J Psychosom Res, 61, 10.1016/j.jpsychores.2006.02.011 Kaptchuk, 2008, Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome, BMJ, 336, 999, 10.1136/bmj.39524.439618.25 Hohannesson, 2011, Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial, Am J Gastroenterol, 106, 915, 10.1038/ajg.2010.480 Johannesson, 2015, Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects, World J Gastroenterol., 21, 10.3748/wjg.v21.i2.600 Bijkerk, 2004, Systematic review: The role of different types of fibre in the treatment of irritable bowel syndrome, Aliment Pharmacol Ther, 19, 245, 10.1111/j.0269-2813.2004.01862.x Furnari, 2015, Optimal management of constipation associated with irritable bowel syndrome, Ther Clin Risk Manag, 11, 691, 10.2147/TCRM.S54298 Moayyedi, 2014, The effect of fiber supplementation on irritable bowel syndrome: A systematic review and meta-analysis, Am J Gastroenterol, 109, 1367, 10.1038/ajg.2014.195 De Roest, 2013, The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: A prospective study, Int J Clin Pract, 67, 895, 10.1111/ijcp.12128 Halmos, 2014, A diet low in FODMAPs reduces symptoms of irritable bowel syndrome, Gastroenterology, 146, 67, 10.1053/j.gastro.2013.09.046 Biesiekierski, 2011, Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial, Am J Gastroenterol, 106, 508, 10.1038/ajg.2010.487 Biesiekierski, 2013, No effects of gluten in patients with self-reported non celiac gluten sensitivity following dietary reduction of low-fermentable, poorly-absorbed, short-chain carbohydrates, Gastroenterology, 145, 10.1053/j.gastro.2013.04.051 Wedlake, 2009, Systematic review: The prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 30, 707, 10.1111/j.1365-2036.2009.04081.x Wong, 2012, Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea, Clin Gastroenterol Hepatol, 10, 1009, 10.1016/j.cgh.2012.05.006 Barkun, 2013, Bile acid malabsorption in chronic diarrhea: Pathophysiology and treatment, Can J Gastroenterol, 27, 10.1155/2013/485631 Camilleri, 2014, Advances in understanding of bile acid diarrhea, Expert Rev Gastroenterol Hepatol, 8, 49, 10.1586/17474124.2014.851599 Wilcox, 2014, Systematic review: The management of chronic diarrhoea due to bile acid malabsorption, Aliment Pharmacol Ther, 39, 923, 10.1111/apt.12684 Tack, 2006, Systematic review: The efficacy of treatments for irritable bowel syndrome – a European perspective, Aliment Pharmacol Ther, 24, 10.1111/j.1365-2036.2006.02938.x Ruepert, 2011, Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 10, CD003460 Martínez-Vázquez, 2012, Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: Systematic review and meta-analysis, Rev Gastroenterol Mex, 77, 82 Annaházi, 2014, Role of antispasmodics in the treatment of irritable bowel syndrome, World J Gastroenterol, 20, 6031, 10.3748/wjg.v20.i20.6031 Ford, 2008, Effect of fiber, antispasmodics, and peppermint oil in irritable bowel syndrome: Systematic review and meta-analysis, BMJ, 337, 1388, 10.1136/bmj.a2313 Khanna, 2014, Peppermint oil for the treatment of irritable bowel syndrome: A systematic review and meta-analysis, J Clin Gastroenterol, 48, 505, 10.1097/MCG.0b013e3182a88357 Clavé, 2011, Randomised clinical trial: Otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome, Aliment Pharmacol Ther, 34, 432, 10.1111/j.1365-2036.2011.04730.x Lopez-Alvarenga, 2013, Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: An analysis with pinaverium bromide 100mg plus simethicone 300mg po bid, Rev Gastroenterol Mex, 78, 21 Wittmann, 2010, Clinical trial: The efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study, Aliment Pharmacol Ther, 31, 615, 10.1111/j.1365-2036.2009.04216.x Ford, 2009, Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and meta-analysis, Am J Gastroenterol, 104, 1831, 10.1038/ajg.2009.223 Garsed, 2014, A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea, Gut., 63, 1617, 10.1136/gutjnl-2013-305989 Evans, 2007, Tegaserod for the treatment of irritable bowel syndrome and chronic constipation, Cochrane Database Syst Rev, CD003960 Tack, 2012, Systematic review: Cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders, Aliment Pharmacol Ther, 35, 745, 10.1111/j.1365-2036.2012.05011.x Keating, 2013, GM1Prucalopride: A review of its use in the management of chronic constipation, Drugs., 73, 1935, 10.1007/s40265-013-0140-1 Kanazawa, 2011, Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome, Neurogastroenterol Motil, 23, 10.1111/j.1365-2982.2011.01732.x Chapman, 2013, Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome, Am J Gastroenterol, 108, 1508, 10.1038/ajg.2013.197 Rao, 2012, A 12 week, randomized, controlled trial with a 4 week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation, Am J Gastroenterol, 107, 1714, 10.1038/ajg.2012.255 Chey, 2012, Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety, Am J Gastroenterol, 107, 1702, 10.1038/ajg.2012.254 Quigley, 2013, Randomised clinical trials: Linaclotide phase 3 studies in IBS-C: A prespecified further analysis based on European Medicines Agency specified endpoints, Aliment Pharmacol Ther, 37, 49, 10.1111/apt.12123 Johanson, 2008, Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 27, 685, 10.1111/j.1365-2036.2008.03629.x Chey, 2012, Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation, Aliment Pharmacol Ther, 35, 587, 10.1111/j.1365-2036.2011.04983.x Corinaldesi, 2009, Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proof-of-concept study, Aliment Pharmacol Ther, 30, 245, 10.1111/j.1365-2036.2009.04041.x Andrews, 2011, Mesalazine (5-.aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome, Aliment Pharmacol Ther, 34, 374, 10.1111/j.1365-2036.2011.04732.x Tuteja, 2012, Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome – a pilot study, Scand J Gastroenterol, 47, 1159, 10.3109/00365521.2012.694903 Dekel, 2013, The use of psychotropic drugs in irritable bowel syndrome, Expert Opin Investig Drugs, 22, 329, 10.1517/13543784.2013.761205 Ford, 2009, Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: Systematic review and meta-analysis, Gut, 58, 367, 10.1136/gut.2008.163162 Ford, 2014, Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis, Am J Gastroenterol, 109, 1350, 10.1038/ajg.2014.148 Vanuystel, 2014, Treatment of abdominal pain in irritable bowel syndrome, J Gastroenterol, 49, 1193, 10.1007/s00535-014-0966-7 Pimentel, 2011, Rifaximin therapy for patients with irritable bowel syndrome without constipation, N Engl J Med, 364, 22, 10.1056/NEJMoa1004409 Pimentel, 2011, Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects, Dig Dis Sci, 56, 2067, 10.1007/s10620-011-1728-5 Boltin, 2014, Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome, Ann Clin Microbiol Antimicrob, 13, 49, 10.1186/s12941-014-0049-x Laterza, 2015, Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome, Expert Opin Pharmacother, 16, 607, 10.1517/14656566.2015.1007951 Kassinen, 2007, The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects, Gastroenterology, 133, 24, 10.1053/j.gastro.2007.04.005 Ford, 2014, Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis, Am J Gastroenterol, 109, 1547, 10.1038/ajg.2014.202 Borody, 2014, Therapeutic faecal microbiota transplantation current status and future developments, Curr Opin Gastroenterol, 30, 97, 10.1097/MOG.0000000000000027 Pinn, 2015, Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?, Neurogastroenterol Motil, 27, 19, 10.1111/nmo.12479 Brandt, 2012, Longterm follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection, Am J Gastroenterol, 107, 1079, 10.1038/ajg.2012.60 Carmona-Sánchez, 2005, Prevalence of use of alternative and complementary medicine in patients with irritable bowel syndrome, functional dyspepsia and gastroesophageal reflux disease, Rev Gastroenterol Mex, 70 Manheimer, 2012, Acupuncture for treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 5, CD005111 Park, 2013, Moxibustion in the management of irritable bowel syndrome: Systematic review and meta-analysis, BMC Complem Altern Med, 13, 247, 10.1186/1472-6882-13-247 Peckham, 2013, Homeopathy for treatment of irritable bowel syndrome, Cochrane Database Syst Rev, 11, CD009710 Lakhan, 2013, Mindfulness-based therapies in the treatment of somatization disorders: A systematic review and meta-analysis, PLoS One, 8, e71834, 10.1371/journal.pone.0071834 Li, 2014, Cognitive-behavioral therapy for irritable bowel syndrome: A meta-analysis, J Psychosom Res, 77, 1, 10.1016/j.jpsychores.2014.03.006 Pajak, 2013, A systematic review of minimal-contact psychological treatments for symptom management in irritable bowel syndrome, J Psychosom Res, 75, 103, 10.1016/j.jpsychores.2013.05.007